Antibody
Drug Conjugates Market is estimated to be worth more than 15 billion in 2030,
predicts Roots Analysis
Antibody
drug conjugates (ADCs) represent a transformative approach to modern cancer
treatment; over the years, this upcoming class of targeted therapeutic agents
has generated significant enthusiasm within the medical science community.
